Drug Profile
Research programme: antibacterial peptide therapeutics - AstraZeneca/PYC Therapeutics
Alternative Names: Phylomer® antibacterials - AstraZeneca/PYC Therapeutics; Pseudomonal infection therapeutics - AstraZeneca/PYC TherapeuticsLatest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator MedImmune; Phylogica
- Developer AstraZeneca; PYC Therapeutics
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pseudomonal-infections in Australia
- 02 Nov 2010 Early research in Pseudomonal infections in Australia (unspecified route)